(Bloomberg) — Polymarket (POLA.PVT) is enlisting firms including Palantir Technologies Inc. (PLTR) to help police its sports contracts, according to people familiar with the matter, a move that comes as prediction markets face intense scrutiny over insider trading. Palantir and TWG (TWG) AI will help Polymarket identify, prevent and report suspicious activity, said the people, who asked not to be identified because the information isn’t public yet. Measures include screening against existing lists of participants already banned from sports betting, the people said. Most Read from Bloomberg The monitoring system will be used on a US-regulated venue that Polymarket is building out, one of the people said. Its main trading platform is situated offshore and does not accept US-based customers. Polymarket and its main rival Kalshi have seen trading volumes explode since last year, driven in large part by sports-related contracts. But questions have arisen over how to monitor and prevent insider trading on everything from elections to geopolitics and sports. In recent years, professional sports leagues including Major League Baseball and the National Basketball Association have grappled with players allegedly colluding with gamblers, and critics say prediction markets are another venue where people with inside information may seek to profit. Up to now, Polymaket had been relatively quiet about how it handles insider trading and other forms of market manipulation. But the exchange founded by Shayne Coplan has been working with IC360, a compliance company that flags unusual betting activity in sports and gaming, people have said. Bloomberg Kalshi has been more vocal. It recently brought two insider trading cases to its regulator, the Commodity Futures Trading Commission. It also formed a committee that will put out quarterly statistics on flagged trades, investigations and cases referred to the government. The rival prediction markets came under scrutiny in recent weeks over...

中国信息通信研究院专家指出，尽管“龙虾”智能体已经更新到最新版本，能修复已知的安全漏洞，但并不意味着完全消除安全风险。工业和信息化部网络安全（885459）威胁和漏洞信息共享平台已经发布过相关安全风险提示。专家呼吁，党政机关、企事业单位和个人用户要审慎使用“龙虾”等智能体。在发现“龙虾”等智能体的安全漏洞，或者针对“龙虾”等智能体的安全威胁和攻击事件时，可以第一时间向工业和信息化部网络安全（885459）威胁和漏洞信息共享平台报送，平台将按照《网络产品安全漏洞管理规定》要求，及时组织处置。(央视新闻)

China’s leading semiconductor executives are calling for a nationwide effort to create a homegrown alternative to ASML Holding N.V. as U.S. restrictions tighten on advanced chip tools. Call For Domestic EUV Ecosystem In an article published in Science and Technology Review, executives from Semiconductor Manufacturing International Corporation (SMIC), Empyrean, Yangtze Memory Technologies (YMTC), and Naura Technology, along with academics, argued that China’s chip sector remains too small, fragmented, and weak, dispersing public resources and slowing progress. Don't Miss: The authors said U.S. restrictions have targeted three key areas of China’s semiconductor industry: electronic design automation (EDA) tools used for chip design, silicon wafers, and manufacturing equipment—particularly extreme ultraviolet (EUV) lithography, a technology dominated by ASML, which cannot export EUV machines to China, SCMP reported on Thursday. Industry Fragmentation They stressed that China must coordinate financial and human resources nationwide to build its own EUV ecosystem and strengthen capabilities in EDA and wafer production, with the effort expected to continue through the 15th Five-Year Plan, which ends in 2030. The article also noted that China’s semiconductor industry remains highly fragmented, with over 100 EDA developers, about 3,600 chip designers, and more than 180 wafer-equipment companies, highlighting the need for stronger collaboration and consolidation across the sector. Trending: Before the IPO: How One Company Quietly Locked Up 500+ Iconic Character Rights ASML Moves Beyond EUV Meanwhile, ASML is charting a new course in the chipmaking industry by venturing into advanced packaging solutions for artificial intelligence (AI) chips. Recently, the company revealed plans to integrate AI into its existing and future operations, aiming to enhance the performance and speed of its tools, which are critical for producing cutting-edge AI processors. Chief Technology Officer...

China’s surge in crude imports early this year has strengthened its stockpiles against a backdrop of rising Middle East tensions and global supply risks. China imported 96.93 million tonnes of crude in January and February, up 15.8 per cent from the same period in 2025, according to customs data released on Tuesday. The value of those imports, meanwhile, fell 5.2 per cent from last year in US dollar terms. “China was accumulating oil and gas stockpiles [earlier this year], with the market expecting the US to strike Iran,” said Chim Lee, senior analyst at the Economist Intelligence Unit. “It built on the record-breaking strong stockpiling momentum we saw in 2025.” Advertisement Since US-Israeli airstrikes on Iran began on February 28, commercial traffic in the Strait of Hormuz - a critical oil artery south of Iran through which about one-fifth of the global supply passes - has largely come to a standstill. The escalating regional conflict has spilled over into other Gulf nations, forcing key refineries in countries such as Saudi Arabia and Iraq to scale back crude production. Advertisement While highly exposed to Middle Eastern oil, China has built a substantial stockpile - which Lee estimated to be around 120 days of import cover - that provides a buffer against potential supply shocks.

China has lowered the operational cost of an anti-drone high-power microwave (HPM) system to just a few yuan per shot, making it a cost-effective option for policing applications, according to a state media report. The launch of an urban police anti-drone swarm microwave defence system marked a further reduction in cost and increased accessibility of HPM technology as it expanded into civilian applications, state broadcaster CCTV said on Saturday. Developed by state-owned 081 Electronics Group, the system integrates radar, electro-optical and radio detection systems with a large flat-panel antenna that elevates and rotates, mounted on an eight-wheel truck. Advertisement The system can “soft kill” incoming drones by jamming or use high-power microwaves for a “hard kill”, instantly overheating and melting the internal chips and metal circuitry for an immediate crash. Drones have increasingly emerged as a source of unconventional public security challenges. For instance, there have been widely reported incidents around the world of the devices being used to drop food or drugs into prisons. In 2018, Chinese authorities uncovered smuggling rings that were using drones to transport an estimated 500 million yuan (US$72 million) worth of illicit electronic goods across the Hong Kong-Shenzhen border.

Xanadu and AMD team up ahead of trading debut. Quantum computing meets aerospace. MSN

When Mojtaba Khamenei was named Iran’s new supreme leader, many observers reacted with surprise. For decades, the son of Ayatollah Ali Khamenei had been a shadowy figure in Iranian politics, rarely seen in public and almost never heard speaking. He has never given interviews, has held no elected office and appears publicly only on rare ceremonial occasions. Even among political insiders, knowledge of his views is fragmentary. What little is known about him consists of scattered anecdotes: brief involvement in the Iran-Iraq war as a young man, occasional appearances in political circles and a long association with figures inside Iran’s security establishment. And yet, at one of the most consequential moments in the Islamic Republic’s history, he has been chosen to lead it. The decision tells us less about Mojtaba Khamenei himself than about the wartime logic now shaping Iran’s ruling system. His selection sends a message of defiance to the US and Israel. After the assassination of Iran’s supreme leader and members of his family in the opening phase of the US-Israel war, the Islamic Republic has chosen continuity over uncertainty. The symbolism is unmistakable: the state will survive the killing of its leader and will continue to be led by a Khamenei. But beneath that symbolic message lies a deeper institutional reality about how power actually works in Iran. The Islamic Republic was founded on explicit rejection of hereditary rule. Ayatollah Ruhollah Khomeini, who led the 1979 revolution, denounced monarchy as “abhorrent to Islam”, and the new system defined itself in opposition to the dynastic politics of Iran’s past. For decades, the idea that the supreme leadership might pass from father to son was widely seen as politically dangerous. Even Ali Khamenei himself reportedly dismissed the possibility. Under normal circumstances, Mojtaba Khamenei would therefore have been an unlikely choice. His public profile is minimal, and he lacks the scholarly reputation traditio...

From energy to food, all of life’s essentials are about to get even more expensive. But just knowing that won’t pay the bills As soon as the attacks on Iran started, the warnings commenced: “Get ready for price shocks. Get ready for the oil price to spike. Oh, no need to get ready – it’s already hit $100 a barrel . Get ready for Russia to claw some circuitous but massive advantage from the fact that everything is on fire, get ready for energy bills to go up.” By about day five, experts were explaining how to lock in your current tariff except, whoops, given the global instability, those tariffs were no longer available. If it felt mercenary to worry about your unit price as people were dying, that’s because it was; but considerations of human decency and proportionality aren’t going to arrest the trajectory of life getting more expensive. Get ready for everything to feed into everything else: rising petrol prices to lead to food inflation, food inflation to lead to stuff inflation. Get ready for wages to be unequal to the cost of living, get ready not to complain about it because you’re lucky to have a wage. Get ready for stock exchanges to crash, get ready to not be entirely sure what scale of economic disaster you’re looking at. Continue reading...

Like the blues in the US, samba in Brazil, rumba in Cuba and plena in Puerto Rico, candombe, Uruguay’s Afro-descendent music, was once reviled, marginalised and even banned – but managed to endure. But while other such genres have for decades formed part of the cultural mainstream across the Americas, only now is candombe experiencing its peak. View image in fullscreen A drone view of the Rueda de Candombe gathering in the streets of Ciudad Vieja in Montevideo, Uruguay. Once confined to the Black neighbourhoods of the capital, Montevideo, candombe groups have spread to every region of the South American country of 3.5 million people, 10% of whom identify as Afro-Uruguayan. One Montevideo group, Rueda de Candombe, has been drawing up to 2,000 people every Monday to listen to a repertory that is entirely national and rooted in the Afro-Uruguayan rhythm. “I think we are at a turning point,” said Claudio Martínez, 47, one of the group’s singers and percussionists. View image in fullscreen Claudio Martínez, a drummer of the Rueda de Candombe, performs at Sala de Naciones La Calenda in Montevideo. The session was part of a special event hosted by Jorge Drexler to film a music video and preview his new material. Rueda de Candombe began performing in a bar about a year ago, but as audiences grew, the city council moved it to Plaza España, a public square. “It’s a tremendously meaningful place,” said Martínez. View image in fullscreen Members of the Lonjas de Ciudad Vieja comparsa prepare their costumes and instruments before the start of the Corso de la Ciudad Vieja in Montevideo. In the 18th and 19th centuries, it was only in the secrecy of homes or at a handful of authorised parades that Africans and their descendants were able to play their drums. One way to escape complaints from neighbours was to practise just outside the city wall – very close to where Rueda de Candombe now performs. Martínez said: “It’s crazy, because when you look around, you realise that in this ve...

Documentary accompanying Tate Britain’s exhibition of the two competing painters comes with approachable expertise and beautiful photography T he actual exhibition is still on at the Tate Britain until mid-April, and of course no one would be so heretical as to suggest not seeing these amazing artworks in the flesh. But if you don’t live in London and/or don’t fancy shuffling round with the thronged masses, then this excellent film treatment is a rewarding experience – if only for the glowing closeups, interesting and erudite commentary from the exhibition curators and complete lack of elbows in ribs or backs of other people’s heads. The film-makers behind the Exhibition on Screen strand, of which this forms part, are past masters at creating elegant and watchable counterparts to the gallery-going experience, and this titan of a show which matches the two early 19th-century masters of British art is no exception. The show pitches itself as outlining the (mostly) friendly contest between the two painters who were born 14 months apart (Turner, slightly older, in 1775, and Constable in 1776), and both show and film rather brilliantly walk us through their common ground and where they diverge. Continue reading...

Training teams to use AI at work has given me a front-row seat to a new kind of professional divide. Some people hand everything over to the machine and stop thinking. Others won’t touch it at all. But there’s a third group. They learn to work with AI critically, treat it like a bright, enthusiastic intern that needs to be managed and supported to do their best work. The difference? It’s rarely technical ability. It’s curiosity. A willingness to experiment, get things wrong, and figure out what AI is actually good at. Here’s what I’ve learned so far. Most people fail with AI because they don’t understand what it actually is The people I’ve worked with tend to swing between extremes: treating AI as an all-knowing oracle or dismissing it entirely after one mistake. Current AI has as much in common with the human brain as a bird has with an A380. Both can fly, but that’s where the similarity ends. Large Language Models simply predict words based on patterns in their training data. It’s why they can produce fluent prose about well-covered topics, but will confidently make things up when they’re on unfamiliar ground. Once users understand this, their approach changes to providing it with clear goals and proper context. When someone tells me everything they get from AI is rubbish, it almost always turns out they’re getting generic answers to generic prompts. The people who get the best results treat AI as a skill, not a shortcut The biggest predictor of success isn’t technical ability. It’s whether someone treats AI as a skill to be learned rather than a magic box that either works or doesn’t. The people best at using it are the ones who experiment daily and reflect on how to get better results next time. The goal is to get the machines to work for us, not to think for us - that means using it in a proactive, critical and engaged way. AI needs direction, feedback and correction – just like people do The skills needed to use AI are ones many people already have: communicat...

In this article ORCL Follow your favorite stocks CREATE FREE ACCOUNT watch now VIDEO 5:44 05:44 Inside Oracle's risky AI bet Tech Oracle reports third-quarter earnings on Tuesday, and it will be an unofficial test for the artificial intelligence trade. Following the announcement of a $50 billion financing plan at the beginning of February that included debt and equity, investors have been eager to understand the pace of dilution for current stockholders. "The cadence matters," said Gil Luria, equity analyst at DA Davidson, told CNBC. Of all the hyperscalers that are leaning into AI cloud computing, Oracle has had to rely the most on financing measures to fund its ambitious data center buildout plans. Its latest debt raise included a $5 billion convertible preferred offering and roughly $25 billion in senior notes at different maturities, according to a credit investor who spoke to CNBC. The deal was oversubscribed, indicating strong demand. Oracle's ability to deliver data center assets to OpenAI , its main customer, is of utmost importance to investors. Late Friday, Bloomberg reported that talks to expand its deal with OpenAI in Abilene, Texas, fell through. A source familiar with the situation told CNBC that Oracle's deal to deliver eight sites to OpenAI remains on track and on schedule. The source asked not to be named in order to discuss a confidential matter. OpenAI executive Sachin Katti later posted on X that while it contemplated expanding its presence in Abilene, it would look to other markets across the U.S. "We considered expanding it further, but ultimately chose to put that additional capacity in other locations," Katti wrote. "Today we have more than half a dozen sites under development across multiple states, including the site we're building with Oracle in Wisconsin, where the first steel beams went up just this week." Katti is in charge of spearheading OpenAI's compute infrastructure and previously held the role of AI chief and chief technology offi...

On a steep hillside in western El Salvador, Oscar Leiva watches rainfall in December, a month that once marked the start of the dry season. During this harvest cycle, flowering came early and then stalled. A heatwave followed. What remains of the crop is uneven, lower in quality and more expensive to produce than the last. For Leiva and his family, coffee has never been just a crop. His mother, Marina Marinero, remembers when the rains arrived on schedule and the harvest could be planned months in advance. Today, the calendar no longer holds. Decisions about pruning, fertilising and hiring labour feel like educated guesses. Each mistake carries a cost the family cannot afford. Q&A What is the Coffee crisis series? Show As the climate crisis deepens, Latin America’s coffee producers – from the steep hillsides of Central America to the forests of Brazil and the Andean slopes of Colombia – are facing an existential threat. While global markets still project an image of abundance, small farmers across the region are struggling with rising costs, unpredictable weather and a shrinking workforce, forcing many to question whether coffee farming remains viable. The climate crisis poses an escalating threat by driving up temperatures in key growing regions. A recent Climate Central analysis found that the world’s five largest producers – Brazil, Vietnam, Colombia, Ethiopia and Indonesia – now face an average of 57 additional days of damaging heat each year. The problem is evident across much of Latin America, a region that includes leading producers such as Brazil, Colombia, Mexico, Honduras, Guatemala and Peru, and accounts for more than half of global output. According to Climate Central, Brazil, the largest producer, now endures 70 more hot days a year. “High temperatures place coffee plants under stress, reducing much of their productive potential. This is affecting coffee plantations around the world, as most are located within the same latitudes,” says Celso Vegro, an a...

政府優化升降機資助計劃推出七年，截至去年10月，只為約一千部升降機完成工程。有議員建議當局調整申請資格，方便更多業主申請。 簡太1976年搬入北角春秧街這座大廈7樓，50年來都是靠同一部升降機出入。升降機是上世紀設計，每層樓都需要打開鐵門，簡太樓層的鐵門油漆已脫落，手柄彎曲，其他樓層的鐵門保養更差，這層更留下曾經火警昏黑的痕跡。 簡太稱：「擔心它會突然停下，要行樓梯。(承辦商)不知怎樣收取舊的，修葺後就幫我們安裝。」 記者問：「其實只是二手零件？」 簡太回應：「沒有一手了。他說原廠都沒有，所以原本三菱都不肯保養了。」 根據立法會最新統計，全港現時有超過7.3萬部升降機，當中有近三萬部機齡已達到30年以上。港島佔最多，有10,893部，九龍就有9,900多部，新界有9,000部。 政府七年前推出優化升降機資助計劃，撥款45.1億元，目標在今年3月或之前，優化或更換8,000部高齡升降機。但截至去年10月，只批出5,700部的申請，僅有1,127部完成。新一份《財政預算案》撥款多10億元延續計劃。 計劃要由業主立案法團或全體業主申請，每部升降機最多獲資助50萬元。不過簡太指，有法團都不一定有共識。 簡太指出：「個個都不在這裡住，召集開會看見就算。如果很大手筆要更換升降機，要夾錢的話，老人家就說沒有本事，子女不肯承擔，唯有等機會。」 有議員認為應調整申請細節。 民建聯香港島東議員植潔鈴認為：「很多舊樓其實沒有法團，甚至業主取得共識都有困難，現在上限50萬元，我們看到更換升降機，支出約100萬元時，會否將資助額提升至六成，即60萬元，起碼業主及法團角度，都會在預算範圍內。」 植潔鈴亦建議，當局可以參考過往大廈修葺外牆做法，即先介入、後付款，加快更換或保養升降機。

A put ratio spread is an advanced option trade and generally not suitable for beginners, but it can have its place within an option portfolio. It is generally considered a neutral strategy, although it has the ability to make a profit in up, down and sideways markets. Yes, it can make money no matter which way the market goes, the key is the timing! The strategy involves buying a number of put options and selling more put options further out-of-the-money. The trade is placed when the trader thinks the underlying stock will be stable or slowly move lower and finish around the short put strike at expiry. A fall in implied volatility will benefit the trade and it can also be profitable if the stock moves up early in the trade. The big risk with the trade is a sharp move lower early in the trade. Let’s look at an example using Microsoft (MSFT). Microsoft Ratio Spread Example Buying the April 17 put with a strike price of $390 for around $7.93 and selling 2 of the April 17, 370-strike puts for around $4.00 would create a put ratio spread. As we are selling 2 contracts at $4.00 the trade results in a net credit of $0.07 which is $7 premium. This is the maximum gain above a stock price of $390. Basically, all the puts would expire worthless and the trader keeps the $7 premium. A tent-shaped profit zone exists between $350 and $390 with the maximum gain occurring at $370 and is around $2,000. This is what the trade looks like as of today: You can see the main risk in the trade is a drop in price early on. The blue line is the profit and loss at expiration and the purple line is the T+0 line. T+0 just means “today”. So, we don’t want the stock to get into the profit tent too early. What about in three week’ time? How does the trade look then? Looking a lot better for any price above $365. One advantage of this trade type is it takes advantage of option skew. Notice the contract we are buying has lower volatility (31.44%) than the contract we are selling (34.14%). Buy low, se...

Oracle earnings will show whether its expensive AI bet is starting to pay off CNBC

CHICAGO, March 10, 2026 (GLOBE NEWSWIRE) -- Amplify ETFs , a leading provider of breakthrough ETF solutions, today announced the launch of the Amplify Municipal CEF High Income ETF (YYYM), which is designed to deliver federally tax-advantaged high monthly income through diversified exposure to ~30 U.S. municipal bond closed-end funds (CEFs). YYYM seeks investment results that generally correspond to the price and yield performance of the Nasdaq Municipal Bond CEF High Income™ Index (the “Index”). The Index measures the performance of 30 U.S. municipal bond closed-end funds selected through a rules-based methodology focused on tax-exempt high income. The methodology prioritizes fund yield, discount to net asset value (NAV), and liquidity in its selection process. Municipal bond closed-end funds are commonly utilized in income-focused portfolios for their ability to generate federally tax-exempt income. CEFs can trade at a discount or premium to NAV, offering the potential to enhance yield and capital appreciation when purchased below the underlying net asset value. YYYM packages this exposure into a single ETF, offering diversified exposure across professionally managed municipal CEFs while aiming to reduce single-fund concentration risk and simplify implementation in taxable accounts. “Attractive after-tax income remains a key consideration for many investors,” said Christian Magoon, CEO of Amplify ETFs. “Municipal closed-end funds can play an important role in taxable portfolios, particularly when accessed through a disciplined framework that incorporates income, valuation, and liquidity. YYYM delivers that exposure through a transparent, systematic approach.” YYYM’s launch extends Amplify’s leadership in the discounted closed-end fund ETF space. Amplify also offers the Amplify CEF High Income ETF (YYY), which aims to pay a high level of monthly income by providing exposure to a variety of CEF asset classes while prioritizing yield, discount to NAV, and liquidity. ...

In the seven and a half years since Apple Inc. ’s market capitalization broke through the $1 trillion mark, investors have become accustomed to seeing big tech companies command 13-digit valuations in public markets. There are more on the way. SpaceX , the space exploration company controlled by Tesla Inc. founder and world’s richest man Elon Musk , has signaled it is planning a mega-initial public offering in the coming months. Artificial intelligence rivals OpenAI and Anthropic also might go public this year, and their private valuations already have soared into the hundreds of billions of dollars. The SpaceX IPO is expected to raise as much as $50 billion, which would shatter the previous record set by Saudi Aramco ’s $29.4 billion listing in 2019. SpaceX could seek a valuation of more than $1.75 trillion, Bloomberg has reported, though whether public-market investors will be prepared to buy shares supporting that valuation remains to be seen. SpaceX has morphed from a relative underdog in the space industry to an aerospace behemoth that receives billions of dollars in government contracts and serves as a backbone for the US space program. In addition to its rocket launch business, SpaceX owns a satellite-based internet broadband service, Starlink, that has become the company’s main cash flow generator. Following an all-stock acquisition in February of xAI, SpaceX also owns Grok, a money-burning AI operation whose flagship product is the Grok AI assistant. X, the microblogging site previously known as Twitter, rounds out its portfolio of businesses. A SpaceX IPO would be a huge market spectacle as investors large and small get a chance to buy into Musk’s fast-evolving vision to create a combined space and AI powerhouse. Yet skeptics say investors might worry that Musk will deplete SpaceX, a company that is the clear leader in its industry, to fund xAI, one of many players in a crowded field. Why is SpaceX planning an IPO? Even though SpaceX is believed to have si...

Barclays says the chasm between winning and losing stocks in 2022 when Russia invaded Ukraine was huge. Here are their style picks.

Changing Social Security to a flat benefit for all would put both workers and the poor at risk.

- Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 - - Reauthorization of FDA’s Rare Pediatric Disease Priority Review Voucher (PRV) program provides opportunity for Opus’ deep pipeline in rare inherited retinal diseases - - FDA Prescription Drug User Fee Act (PDUFA) date in October 2026 for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia - - Funding from prominent healthcare investors expected to extend cash runway into 2028 - RESEARCH TRIANGLE PARK, N.C., March 10, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced financial results for the year ended December 31, 2025, and provided a corporate update. “We are delivering a steady cadence of data and milestones across our pipeline,” said George Magrath, M.D., Chief Executive Officer, Opus Genetics. “With positive clinical results from both our BEST1 and LCA5 gene therapy programs, new funding for our MERTK program and an upcoming FDA PDUFA date for Phentolamine Ophthalmic Solution 0.75% in presbyopia, we are advancing therapies with both scientific promise and compelling commercial potential. The reauthorization of the U.S. Rare Pediatric Disease Priority Review Voucher program further strengthens our work, reinforcing long‑term incentives that support sustainable investment in rare gene therapy development. With multiple catalysts ahead and a capital‑efficient operating model, we believe Opus is positioned to create significant long‑term value for shareholders.” Pipeline Updates OPGx-BEST1 – Gene Therapy for BEST1-Related IRD Recruitment is ongoing at multiple U.S. sites with two participants treated to date in the Phase 1/2 trial (BIRD-1) that includes p...

NEWARK, N.Y., March 10, 2026 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) reported operating results for the fourth quarter and full year ended December 31, 2025 as follows: Fourth Quarter: Sales of $48.5 million compared to $43.9 million for the 2024 fourth quarter Gross profit of $12.1 million, or 24.9% of revenue, compared to $10.6 million, or 24.2% of revenue, for the 2024 fourth quarter Operating (loss) income of ($10.6) million, which includes a ($12.2) million intangible asset impairment charge and ($1.2) million of one-time costs, compared to $1.5 million for the 2024 fourth quarter GAAP EPS of ($0.45), which includes ($0.57) for the intangible asset impairment charge net of the related tax benefits, compared to $0.01 for the 2024 fourth quarter Adjusted EBITDA of $5.7 million compared to $3.9 million for the 2024 fourth quarter Backlog of $110.2 million exiting 2025 compared to $90.3 million exiting the third quarter “During the fourth quarter we took a number of decisive actions to remove structural and manufacturing inefficiencies from our global operations. For example, we commenced the realignment of our four thionyl chloride/oil & gas operations into one business within our Battery & Energy Products segment focused on industrial, specialty and telemetry solutions in order to optimize synergies, deepen customer engagement and expand value propositions. We also designed a master brand strategy uniting all acquired sub-brands under the Ultralife brand and aligning sales of the total Ultralife portfolio, and we completed steps to strengthen the operational leadership at our two largest manufacturing facilities. While we were intensely focused on addressing operational improvements during the quarter, strong order flow increased backlog to $110 million at the end of 2025, representing a 22% increase over the third quarter,” said Mike Manna, President and Chief Executive Officer. “As a result, we have entered 2026 from a position of strength, bett...

Achieved randomization target of 230 patients in LEVEL study, topline data expected in third quarter of 2026 Initiated global Phase 3 LEVEL-2 clinical trial and opened long-term OLE study for patients to remain on drug CHAPEL HILL, N.C., March 10, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, reported today financial results for the year ended December 31, 2025 and provided an update on its recent corporate progress. “We are pleased to announce that we have recently achieved our randomization target of 230 patients in the Phase 3 LEVEL study. As we strive to make significant progress executing on our registrational LEVEL program, achievement of this important milestone demonstrates our team’s commitment to rapidly advancing TNX-103,” said Chris Giordano, President and Chief Executive Officer of Tenax Therapeutics. “The screening period for LEVEL has closed. Patients already screening will have the opportunity to qualify for randomization, which we anticipate finishing this month. We expect to share initial results from LEVEL in the third quarter of 2026.” Mr. Giordano continued, “In parallel, we remain focused on activating clinical sites around the world to advance the global LEVEL-2 study, which we continue to anticipate will complete enrollment by the end of 2027. With a continued focus on execution, we aim to rapidly advance the development of TNX-103, a novel and potential first-in-class therapy for patients with PH-HFpEF who have no approved treatment options for their debilitating disease.” Recent Corporate and Clinical Highlights In November 2025, Tenax hosted a virtual call with key opinion leaders to discuss the treatment landscape for pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF), as well as its Phase 3 TNX-103 program. In Decembe...

RAP-219’s lead program demonstrated robust and consistent activity in patients with focal onset seizures (FOS) in Phase 2a trial; initiation of Phase 3 program expected in the second quarter of 2026 RAP- 219 epilepsy portfolio expanded with new program in primary generalized tonic-clonic seizures (PGTCS) on strength of Phase 2a FOS data Phase 2 trial in bipolar mania, development of a long-acting injectable, and other pipeline programs continued to progress Entered into a strategic collaboration and license agreement with Tenacia Biotechnology (Hong Kong) Co., Ltd. to develop and commercialize RAP-219 in Greater China across indications, including focal onset seizures and bipolar mania Ended the year with $490.5 million in cash, cash equivalents, and short-term investments, excluding restricted cash, which is expected to fund operations into the second half of 2029 BOSTON and SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological and psychiatric disorders, today reported financial results for the quarter and full year ended December 31, 2025, and provided a business update. “2025 was a year of strong momentum for Rapport as we advanced our precision neuroscience pipeline and continued building what we believe can become a leading epilepsy portfolio. The compelling Phase 2a results in focal onset seizures strengthened our confidence in the program’s potential best-in-class profile and support our strategy to advance RAP-219 across multiple opportunities within epilepsy,” said Abraham N. Ceesay, chief executive officer of Rapport. “We also continued to advance several other important initiatives, including our Phase 2 bipolar mania trial, development of a long-acting injectable formulation, and additional pipeline candidates - applying our precision medicine...

MIDDLETOWN, R.I., March 10, 2026 (GLOBE NEWSWIRE) -- KVH Industries, Inc., (Nasdaq: KVHI), reported financial results for the quarter and full year ended December 31, 2025 today. The company will hold a conference call to discuss these results at 9:00 a.m. ET today, which can be accessed at investors.kvh.com. Following the call, a replay of the webcast will be available through the company’s website. Fourth Quarter 2025 Highlights Total revenues in the fourth quarter of 2025 increased sequentially from the third quarter of 2025 by $2.1 million, or 7%, to $30.5 million primarily due to an increase in service sales. Total revenues increased by 13% from $26.9 million in the fourth quarter of 2024, primarily due to a $6.0 million increase in service sales, partially offset by a $2.4 million decrease in product sales. Service revenue increased sequentially from the third quarter of 2025 by $2.9 million, or 12%, to $28.3 million in the fourth quarter of 2025. Service revenue increased by $6.0 million, or 27%, in the fourth quarter of 2025 compared to the fourth quarter of 2024. On October 8, 2025, the Company purchased the maritime satellite service business of a satellite services provider operating in the Asia-Pacific region. As a result of the business combination, the Company recognized intangible assets of $3.4 million and goodwill of $0.7 million. Service revenue in the fourth quarter of 2025 included $2.5 million of revenue attributable to the business combination. Net income in the fourth quarter of 2025 was $0.3 million, or $0.02 per share, compared to a net loss of $4.3 million, or $0.22 per share, in the fourth quarter of 2024. Non-GAAP adjusted EBITDA was $3.1 million in the fourth quarter of 2025, compared to $0.5 million in the fourth quarter of 2024. Commenting on the company’s fourth quarter and full year results, Brent C. Bruun, KVH’s Chief Executive Officer, said, “The maritime connectivity market is undergoing a fundamental transformation as LEO satelli...

CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $555 million and $1.9 billion for the fourth quarter and full year 2025, respectively (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $555 million and $1.9 billion for the fourth quarter and full year 2025, respectively Surpassed milestone of more than 10,000 patients treated with CARVYKTI ® CARVYKTI now available across 294 sites worldwide; continued expansion in U.S. community settings Advanced early-stage cell therapy portfolio, including first-patient dosing of in vivo candidates and presentation of first-in-human results for LUCAR-G39D, an allogeneic CAR-T therapy Cash and cash equivalents, and time deposits of $949 million, as of December 31, 2025 SOMERSET, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported financial results for the fourth quarter and year ended December 31, 2025, and key corporate highlights. “CARVYKTI® continued to build on its leadership in multiple myeloma CAR‑T in 2025, as we reached more than 10,000 patients treated and achieved franchise profitability,” said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. “With expanding capacity and ongoing efforts to broaden adoption, including in the community setting, we are focused on executing against the opportunities ahead while extending our innovation leadership across in vivo and allogeneic programs.” Key Business Developments Achieved CARVYKTI ® franchise profitability for the full year 2025. franchise profitability for the full year 2025. Treated more than 10,000 clinical and commercial patients to date with CARVYKTI ® . . Strengthened manufacturing and supply capabilities, completing the newly expanded portion of the Raritan facility, making it the largest cell therapy manufacturing site in the United States supporting treatment of up to 10,000 patients annually. Expanded gl...

Transition Underway to More Digital, Scalable, Higher Margin Business Fourth quarter Revenue of $77.2 million driven primarily by record Interactive revenue, up 53% year-over-year Fourth quarter Net Operating Income of $11.2 million, Net Loss of $7.2 million and Adjusted Net Loss of $5.1 million Adjusted EBITDA of $32.3 million, up 5% from prior year, generating a record 42% Adjusted EBITDA Margin, driven by all-time-high Interactive Adjusted EBITDA, up 60% year-over-year First quarter 2026 Adjusted EBITDA expected to increase by at least 20% year over year, with full year 2026 Adjusted EBITDA expected to be in the range of $112 million to $118 million1 NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Inspired Entertainment, Inc. (“Inspired” or the “Company”) (NASDAQ: INSE), a leading B2B provider of gaming content, technology, hardware and services, today reported financial results for the fourth quarter and fiscal year ended December 31, 2025. “Our fourth quarter results reflect the strength of our underlying business and the progress we are making in advancing our strategic priorities,” said Brooks Pierce, President and CEO of Inspired. “We delivered record Interactive revenue (+53% YoY) and Adjusted EBITDA (+60% YoY), underscoring the scalability and operating leverage of our digital core growth engine. With digital representing 52% of Adjusted EBITDA2 following the November divestiture of our holiday parks business, we achieved a record Adjusted EBITDA margin for the quarter3. Content continues to be a key differentiator across the portfolio. In Gaming, customers with new terminal deployments in our UK and Greece estates delivered double-digit gross win growth, supporting further share gains. In Virtual Sports, our new Virtual Soccer BetBuilder™ product in Greece is still in its early stages but is already driving increases in total bet volume and gross win, positioning us well for a broader rollout ahead of this summer’s World Cup. We remain focused on investing i...

Initial clinical data for CLN-978 in SLE and RA confirmed for Q2 2026; repeat dosing data in RA confirmed for Q3 2026 Zipalertinib rolling NDA submission completed; enrollment of REZILIENT3 frontline study completed with top-line results available by year-end 2026 Cash and investments of $439.0 million as of December 31, 2025; runway into 2029 CAMBRIDGE, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today provided an update on recent and anticipated business highlights and announced its financial results for the fourth quarter and full year ended December 31, 2025. “Cullinan Therapeutics is poised to deliver multiple value-driving catalysts across our programs throughout 2026. Strong enrollment momentum for CLN-978 positions us to deliver the first company-sponsored data for a potential best-in-class CD19 T cell engager in autoimmune diseases in the second quarter, followed by important additional data updates throughout the year. CLN-978 is the ideal therapy for immune reset, with the optimal combination of target, CD19, and modality, T cell engager, together with the convenience of subcutaneous administration. This program has the potential to transform the treatment landscape in autoimmune diseases and deliver a compelling commercial opportunity,” said Nadim Ahmed, President and CEO of Cullinan Therapeutics. “We are also pleased to begin the year with strong momentum in our oncology portfolio. With our partner, Taiho, we have completed the second line rolling NDA submission for zipalertinib and have fully enrolled the frontline study, REZILIENT3, both important milestones as zipalertinib moves closer to being available for patients. Finally, after sharing compelling clinical data at ASH 2025 and with U.S. FDA Fast Track Designation, we expect to rapidly advance CLN-0...

Created by Mitch Gould, Founder & CEO of Nutritional Products International, a Proven Model for Building Retail Success in the U.S. Market BOCA RATON, FL / ACCESS Newswire / March 10, 2026 / Mitch Gould, Founder and CEO of Nutritional Products International (NPI), developed the Evolution of Distribution®, a comprehensive market-entry system designed to help international health, wellness, and nutritional brands successfully launch and scale within the U.S. retail marketplace. After decades working with major retailers including Walmart, CVS, Amazon, and GNC, Gould recognized a recurring challenge for global brands: entering the U.S. requires navigating a fragmented network of logistics providers, regulatory consultants, distributors, brokers, marketing agencies, and retail buyers. "The Evolution of Distribution® was created to solve that fragmentation," said Gould. "Instead of brands managing multiple vendors across logistics, compliance, sales, and marketing, we built a unified system that brings every step of U.S. market entry under one coordinated program." Today, the Evolution of Distribution® platform has expanded to provide true end-to-end market entry management, beginning at a brand's international manufacturing facility and extending all the way to U.S. retail shelves and e-commerce platforms. Through enhanced logistics and freight-forwarding capabilities, NPI can now coordinate international transportation from virtually any origin worldwide, moving products via ocean, air, rail, or intermodal freight directly to the Port of Miami and into NPI's U.S. warehouse network. From there, products move through a coordinated system that includes regulatory preparation, distribution, retail introductions, and integrated marketing support. Image Caption: Mitch Gould, founder and CEO of Nutritional Products International (NPI) The Evolution of Distribution® model operates through several core pillars designed to support successful product launches and long-term brand ...

"Accelerating quantum applications for the aerospace industry requires close collaboration between quantum software and high-performance computing," said Christian Weedbrook, Founder and Chief Executive Officer of Xanadu. "Our partnership with AMD brings these capabilities together to address real engineering challenges today. By optimizing how large-scale quantum programs are compiled and simulated, we are helping ensure the aerospace industry is ready to adopt fault-tolerant quantum computing as soon as it becomes available.” “Seeing AMD high-performance compute boost the performance of PennyLane is a clear proof point of how quantum and classical technologies can effectively work together,” said Madhu Rangarajan, Corporate Vice President, Compute and Enterprise AI, AMD. “This work further underscores the importance of seamless integration between classical and quantum computing. The work between AMD and Xanadu expands the boundaries of what is possible for users investigating hybrid quantum/classical computing using AMD compute today.” Aerospace engineers rely on computational fluid dynamics (CFD) simulations to optimize design and enhance aircraft efficiency. Xanadu, powered by the AMD DevCloud, has successfully demonstrated CFD simulations within a hybrid quantum-classical program, showcasing the significant potential of quantum computing for the industry. The work centered on the compilation and execution of a CFD model with 256x256 matrix elements. This hybrid program utilized 20 qubits and approximately 35 million quantum gates, pushing the boundaries of current CFD quantum simulations. As the industry advances toward fault-tolerant quantum computing, the ability to compile and optimize programs of this scale will become a critical competitive advantage. This milestone demonstrates that Xanadu and AMD can support next-generation quantum-classical applications by combining their respective technologies and expertise, helping transition quantum computing from ...